![]() |
市場調查報告書
商品編碼
2170130
2026 年至 2035 年紙漿酶的市場機會、成長要素、產業趨勢與預測。Paper & Pulp Enzymes Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 |
||||||
預計到 2025 年,造紙和紙漿酶市場規模將超過 3.5 億美元,年複合成長率為 8%,到 2035 年將達到 7.558 億美元。
| 市場範圍 | |
|---|---|
| 開始年份 | 2025 |
| 預測期 | 2026-2035 |
| 初始市場規模 | 3.5億美元 |
| 預測金額 | 7.558億美元 |
| 複合年成長率 | 8% |
隨著紙漿產量的擴大,漂白和纖維加工中需要酵素處理的製程數量也在增加。採購量與特定生產階段的加工量密切相關,而需求又與設備運轉率和新增產能緊密相連。再生纖維的日益普及進一步增加了對油墨去除、纖維分離、雜質控制和紙張運作性能的需求。處理更多種類再生原料的造紙廠需要能夠提高產量和製程穩定性的配方。耐熱耐鹼木聚醣酶的開發拓展了酵素的應用範圍。與高要求的牛皮紙製程的兼容性減少了對冷卻、稀釋或改變給藥位置的需求。這使得即使在製程柔軟性有限的工廠中,酵素的應用也更加切實可行。因此,商業性機會在於將不斷成長的加工量與能夠改善整合並支援再生纖維運行的配方相結合。
依酵素類型分類,木聚醣酶和半纖維素酶的市場規模預計到2035年將達到2.645億美元。其在牛皮紙製漿製程的成熟應用支撐了漂白和纖維改質領域的需求。儘管該類別已獲得廣泛認可,但造紙廠仍不斷要求提高其對操作條件的耐受性。供應商需要在保持酶活性的同時,降低將加工步驟整合到生產線中的複雜性。因此,該商業性提案將成熟的工作流程與進一步的配方開發相結合。買家會評估該產品是否無需進行不必要的調整即可應用於預期製程。嚴苛條件下的性能和實際整合性,以及該酵素家族的現有作用,都會影響購買決策,並支持那些尋求在其生產過程中進行可靠加工的工廠繼續使用該酶。
用途別に見ると、バイオ漂白市場は2035年までに2億4,190万米ドルに達すると予測されています。その役割は、漂白工程の経済性と製紙工場における環境管理に関連しています。導入の成否は、過酷なクラフト紙製造条件下でも活性を維持できる配合にますます依存するようになっています。購入者は、操業を複雑にする工程を追加することなく、処理上のメリットを得ようとしています。したがって、この用途の商業性的な位置づけには、化学薬品の使用削減という目標と、実用的な操業上の適合性の両方が関わってきます。サプライヤーは、酵素の性能と実際の製紙工場における工程上の制約とを結びつける必要があります。既存の条件に適合する製品は、導入に向けたより現実的な道筋を提供できるため、配合の接受度や技術サポートは、バイオ漂白プログラムへの参画において重要な要素となります。
預計到2035年,北美紙漿和造紙酶市場規模將達到1.967億美元。成熟的牛皮紙造紙工藝與完善的再生纖維基礎設施和現有的技術服務相結合。包裝紙、瓦楞紙板和衛生紙是主要需求來源。造紙廠在維持機器性能的同時,力求提高再生纖維的使用率,這就需要製程支援和合適的配方。因此,該地區的商機在於改進現有工廠中再生纖維的處理方式。供應商擁有成熟的營運體系,能夠滿足客戶對符合績效目標的加工需求。技術支援有助於選擇合適的酵素及其與運作和纖維加工要求的兼容性,從而支援在成熟的造紙生產環境中實施。
ノボネシス社は2025年に26%の市場シェアを占めました。同社の產品系列は、漂白、繊維改質、デンプン処理、および不純物制御に及びます。この幅広い製品群により、主要な製紙工場顧客における複数の用途にわたる販売が支えられています。酵素工学の規模と技術サービスは、複雑な導入プログラムに参加する同社の能力を強化しています。したがって、同社の競合上の強みは、配合能力と、生産の各段階において製品を活用するために必要なサポートを結びつけている点にあります。複数の処理ニーズを検討している製紙工場は、個別の添加剤のみではなく、より広範なサプライヤーとの関係構築を検討することができます。同社の商業性的な重要性は、さまざまなワークフローにおいて酵素の性能を実際の製紙工場の操業に反映させる上で、アプリケーション研究所、現場支援、そして確立された客戶參與がいかに重要であるかを示しています。
市場的主要參與者包括IFF Health and Biosciences、Solenis、AB Enzymes GmbH、Buckman Laboratories International、Advanced Enzyme Technologies Ltd.、Maps Enzymes Ltd.、Sunson Industry Group Co., Ltd.、Amano Enzyme Inc.、山東隆克酶業有限公司、MetGen Oy、Foorzym、Minak、Minzying、Makzy) Enzymes。 IFF提供工業生物技術,Solenis整合酶和製程化學品,Buckman專注於劑量控制和製程控制,而區域性製造商則致力於滿足當地的供應和成本需求。每家專業公司都專注於脫墨工藝、嚴苛的操作條件或定製配方。競爭對手越來越重視技術支援、發酵能力、應用效能以及與當地造紙廠的合作網路等因素。
The Paper and Pulp Enzymes Market exceeded USD 350 million in 2025 and is projected to grow at 8% CAGR to reach USD 755.8 million by 2035.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $350 Million |
| Forecast Value | $755.8 Million |
| CAGR | 8% |
Expanding pulp production increases the process base requiring enzymes in bleaching and fiber treatment. Purchases follow throughput at defined production stages, linking demand with utilization as well as new capacity. Greater use of recovered fiber creates additional requirements for ink removal, fiber liberation, contaminant control, and runnability. Mills handling more variable secondary materials need formulations that support yield and process stability. Engineering of thermostable and alkali-tolerant xylanases also expands the conditions under which enzymes can be used. Compatibility with demanding kraft sequences can reduce the need for cooling, dilution, or changed dosing locations. This makes adoption more practical for facilities with limited process flexibility. The commercial opportunity consequently combines higher treatment volumes with formulations that improve integration and support recycled-fiber operations.
Based on enzyme type, xylanases and hemicellulases are projected to reach USD 264.5 million by 2035. Established use in kraft operations supports demand across bleaching and fiber modification. The category benefits from installed familiarity, but mills continue to seek improved tolerance of operating conditions. Suppliers need to maintain enzyme activity while reducing the complexity of incorporating treatment into production. The commercial proposition therefore connects established workflows with further formulation development. Buyers assess whether products can serve the intended process without adding unnecessary adjustments. Performance under demanding conditions and practical integration influence purchasing alongside the enzyme family's existing role, supporting continued application across facilities seeking dependable treatment within their production sequence.
By application, biobleaching is projected to reach USD 241.9 million by 2035. Its role is linked to the economics of bleaching sequences and environmental management at mills. Adoption increasingly depends on formulations that remain active under demanding kraft conditions. Buyers seek to obtain the treatment benefit without adding process steps that complicate operations. The application's commercial position therefore involves both chemical reduction objectives and practical operating suitability. Suppliers must connect enzyme performance with the constraints of the actual mill sequence. Products that fit existing conditions can provide a more workable route to implementation, making formulation tolerance and technical support important to participation in biobleaching programs.
The North America paper and pulp enzymes market is projected to reach USD 196.7 million by 2035. Mature kraft operations combine with established recovered-fiber infrastructure and available technical services. Packaging, containerboard, and tissue provide important demand settings. Mills seek to increase recycled-fiber use while preserving machine performance, creating requirements for process support and appropriate formulations. The regional commercial opportunity consequently involves improving the handling of secondary fiber within existing facilities. Suppliers can address customers with established operating systems who need treatments aligned with performance targets. Technical engagement helps connect enzyme selection with runnability and fiber-processing requirements, supporting implementation in a developed paper-production environment.
Novonesis held a 26% market share in 2025. Its portfolio spans bleaching, fiber modification, starch treatment, and contaminant control. This breadth supports sales across several applications within substantial mill accounts. Enzyme-engineering scale and technical services strengthen its ability to participate in complex implementation programs. The company's competitive position therefore links formulation capabilities with the support needed to use products across production stages. Mills evaluating several treatment needs can consider a broader supplier relationship rather than separate additives alone. Its commercial relevance reflects the importance of application laboratories, field assistance, and established customer engagement in translating enzyme performance into practical mill operations across different workflows.
Some of the major players in this market are IFF Health and Biosciences, Solenis, AB Enzymes GmbH, Buckman Laboratories International, Advanced Enzyme Technologies Ltd., Maps Enzymes Ltd., Sunson Industry Group Co., Ltd., Amano Enzyme Inc., Shandong Lonct Enzymes Co., Ltd., MetGen Oy, EDT Enzymatic Deinking Technologies, Jiangsu Boli Bioproducts Co., Ltd., Noor Enzymes, and Creative Enzymes. IFF contributes industrial biotechnology, while Solenis integrates enzymes with process chemicals. Buckman emphasizes dosing and process control, and regional manufacturers address local supply and cost requirements. Specialists focus on deinking, demanding operating conditions, or customized formulations. Competition increasingly involves technical support, fermentation capability, application performance, and access to regional mill relationships.